Nifty
Sensex
:
:
12987.00
44259.74
128.60 (1.00%)
431.64 (0.98%)

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 532612 | NSE: INDOCO

264.85
26-Nov-2020
  • Open
  • High
  • Low
  • Previous Close
  •  267.00
  •  274.00
  •  264.25
  •  264.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  89424
  •  239.79
  •  296.00
  •  143.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,441.52
  • 42.72
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,665.30
  • 0.11%
  • 3.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 58.69%
  • 2.88%
  • 19.04%
  • FII
  • DII
  • Others
  • 2.22%
  • 14.43%
  • 2.74%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.68
  • 1.88
  • 2.03

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.98
  • -6.37
  • -1.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -7.19
  • -21.70
  • -16.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.43
  • 30.87
  • 33.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.60
  • 3.38
  • 2.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.35
  • 17.14
  • 18.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
328.24
292.57
12.19%
275.86
252.68
9.17%
271.99
252.05
7.91%
289.35
262.64
10.17%
Expenses
267.52
259.94
2.92%
227.21
230.26
-1.32%
238.70
223.65
6.73%
254.48
237.92
6.96%
EBITDA
60.72
32.63
86.09%
48.65
22.42
116.99%
33.29
28.40
17.22%
34.87
24.72
41.06%
EBIDTM
18.50%
11.15%
17.64%
8.87%
14.01%
14.01%
12.05%
9.41%
Other Income
0.52
0.58
-10.34%
0.26
0.64
-59.38%
0.50
4.95
-89.90%
0.72
0.56
28.57%
Interest
5.89
5.37
9.68%
5.75
6.12
-6.05%
7.83
4.63
69.11%
6.93
3.73
85.79%
Depreciation
18.57
18.04
2.94%
19.13
16.99
12.60%
18.20
19.47
-6.52%
17.59
17.72
-0.73%
PBT
36.78
9.80
275.31%
24.03
-0.05
-
7.76
9.25
-16.11%
11.07
3.83
189.03%
Tax
11.13
1.99
459.30%
6.99
-1.90
-
2.40
-2.24
-
1.97
-1.44
-
PAT
25.65
7.81
228.43%
17.04
1.85
821.08%
5.36
11.49
-53.35%
9.10
5.27
72.68%
PATM
7.81%
2.67%
6.18%
0.73%
7.11%
7.11%
3.15%
2.01%
EPS
2.78
0.85
227.06%
1.85
0.20
825.00%
0.58
1.25
-53.60%
0.99
0.57
73.68%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Jun 06
Jun 05
Net Sales
1,165.44
1,106.58
968.45
1,041.94
1,074.77
1,008.12
857.32
732.61
630.79
243.43
194.15
Net Sales Growth
9.95%
14.26%
-7.05%
-3.05%
6.61%
17.59%
17.02%
16.14%
159.13%
25.38%
 
Cost Of Goods Sold
4,898.74
330.43
320.25
347.83
361.27
350.01
300.44
271.98
262.57
104.32
81.04
Gross Profit
-3,733.30
776.15
648.19
694.11
713.49
658.12
556.87
460.63
368.22
139.10
113.10
GP Margin
-320.33%
70.14%
66.93%
66.62%
66.39%
65.28%
64.95%
62.88%
58.37%
57.14%
58.25%
Total Expenditure
987.91
985.74
891.80
910.37
920.27
840.17
691.81
614.44
538.15
198.37
154.21
Power & Fuel Cost
-
34.75
28.49
26.62
23.12
21.72
20.39
18.26
16.37
7.32
4.17
% Of Sales
-
3.14%
2.94%
2.55%
2.15%
2.15%
2.38%
2.49%
2.60%
3.01%
2.15%
Employee Cost
-
256.51
231.66
220.91
216.67
181.87
140.04
129.54
107.87
25.71
20.09
% Of Sales
-
23.18%
23.92%
21.20%
20.16%
18.04%
16.33%
17.68%
17.10%
10.56%
10.35%
Manufacturing Exp.
-
114.63
107.07
101.94
96.38
85.18
52.92
40.58
34.30
14.25
9.22
% Of Sales
-
10.36%
11.06%
9.78%
8.97%
8.45%
6.17%
5.54%
5.44%
5.85%
4.75%
General & Admin Exp.
-
127.76
110.92
110.04
116.40
102.56
90.39
83.49
66.64
25.10
22.56
% Of Sales
-
11.55%
11.45%
10.56%
10.83%
10.17%
10.54%
11.40%
10.56%
10.31%
11.62%
Selling & Distn. Exp.
-
89.28
62.75
70.53
73.22
55.89
51.00
47.83
33.02
15.97
12.76
% Of Sales
-
8.07%
6.48%
6.77%
6.81%
5.54%
5.95%
6.53%
5.23%
6.56%
6.57%
Miscellaneous Exp.
-
32.38
30.66
32.49
33.20
42.94
36.63
22.75
17.38
5.70
12.76
% Of Sales
-
2.93%
3.17%
3.12%
3.09%
4.26%
4.27%
3.11%
2.76%
2.34%
2.25%
EBITDA
177.53
120.84
76.65
131.57
154.50
167.95
165.51
118.17
92.64
45.06
39.94
EBITDA Margin
15.23%
10.92%
7.91%
12.63%
14.38%
16.66%
19.31%
16.13%
14.69%
18.51%
20.57%
Other Income
2.00
4.80
6.70
8.05
5.93
4.03
1.71
3.97
1.50
10.02
4.81
Interest
26.40
26.25
21.09
23.51
6.21
12.39
10.58
18.92
21.87
5.79
3.75
Depreciation
73.49
70.82
71.57
67.71
63.28
60.66
47.09
30.90
23.72
6.32
4.34
PBT
79.64
28.57
-9.31
48.40
90.94
98.93
109.55
72.32
48.55
42.96
36.65
Tax
22.49
4.45
-6.41
7.24
13.87
16.99
26.73
14.28
5.79
11.47
11.61
Tax Rate
28.24%
15.58%
68.85%
14.96%
15.25%
17.17%
24.40%
19.75%
11.93%
26.70%
31.68%
PAT
57.15
24.12
-2.90
41.16
77.06
81.94
82.81
57.98
42.72
31.49
25.04
PAT before Minority Interest
57.15
24.12
-2.90
41.16
77.06
81.94
82.81
58.03
42.76
31.49
25.04
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-0.05
-0.04
0.00
0.00
PAT Margin
4.90%
2.18%
-0.30%
3.95%
7.17%
8.13%
9.66%
7.91%
6.77%
12.94%
12.90%
PAT Growth
116.31%
-
-
-46.59%
-5.96%
-1.05%
42.83%
35.72%
35.66%
25.76%
 
EPS
6.20
2.62
-0.31
4.46
8.36
8.89
8.98
6.29
4.63
3.42
2.72

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Jun 06
Jun 05
Shareholder's Funds
679.57
660.62
674.98
651.34
576.52
518.80
457.15
414.17
198.38
175.31
Share Capital
18.43
18.43
18.43
18.43
18.43
18.43
18.43
18.43
11.82
11.82
Total Reserves
661.14
642.19
656.55
632.91
558.08
500.37
438.72
395.74
186.56
163.49
Non-Current Liabilities
101.00
116.42
125.34
147.04
66.28
64.65
69.87
78.22
53.79
59.52
Secured Loans
96.93
128.66
123.28
132.31
34.24
9.42
7.20
21.41
26.45
30.37
Unsecured Loans
0.00
0.00
0.00
0.00
3.64
3.44
6.59
5.97
9.81
19.39
Long Term Provisions
27.14
15.95
23.77
30.91
40.63
15.04
16.36
6.82
0.00
0.00
Current Liabilities
458.99
445.50
417.36
390.39
302.95
262.12
202.15
199.28
58.53
50.09
Trade Payables
165.60
170.72
149.55
164.03
131.31
119.86
70.66
68.26
41.06
34.19
Other Current Liabilities
135.81
117.13
119.66
72.16
57.38
40.97
53.98
51.34
7.40
7.32
Short Term Borrowings
105.98
113.39
109.93
118.36
87.23
75.38
57.96
64.84
0.00
0.00
Short Term Provisions
51.59
44.26
38.22
35.84
27.03
25.92
19.54
14.84
10.07
8.58
Total Liabilities
1,239.56
1,222.54
1,217.68
1,188.77
945.75
845.57
729.42
691.87
310.70
284.92
Net Block
589.74
467.65
488.86
439.89
373.64
339.80
325.43
321.55
138.99
83.28
Gross Block
1,126.76
934.65
885.11
769.65
641.95
547.64
481.56
447.06
165.56
103.94
Accumulated Depreciation
537.02
467.00
396.25
329.75
268.32
207.84
156.13
125.51
26.57
20.65
Non Current Assets
676.45
684.49
678.73
616.72
481.20
460.22
424.85
416.36
143.54
96.15
Capital Work in Progress
50.70
185.43
135.56
90.63
54.80
62.71
44.12
37.78
4.55
12.86
Non Current Investment
0.02
0.02
0.02
0.02
0.02
0.17
0.17
0.12
0.00
0.00
Long Term Loans & Adv.
26.16
22.01
33.92
66.46
48.15
57.31
54.88
56.59
0.00
0.00
Other Non Current Assets
9.83
9.38
20.36
19.72
4.60
0.22
0.25
0.31
0.00
0.00
Current Assets
563.10
538.05
538.96
572.05
464.55
385.36
304.56
275.51
166.28
187.37
Current Investments
0.00
0.00
0.00
0.00
15.68
0.00
0.00
0.00
6.33
40.07
Inventories
208.32
183.45
193.38
186.94
166.69
149.12
110.22
93.18
35.60
30.11
Sundry Debtors
210.14
195.84
209.51
215.68
188.83
155.38
138.13
127.08
83.41
74.07
Cash & Bank
37.93
36.26
11.90
62.59
12.63
15.40
13.39
13.99
25.20
28.58
Other Current Assets
106.71
15.55
6.46
17.64
80.72
65.46
42.83
41.25
15.73
14.54
Short Term Loans & Adv.
97.60
106.96
117.71
89.21
72.06
61.13
38.68
35.29
15.73
14.54
Net Current Assets
104.12
92.55
121.60
181.66
161.60
123.23
102.41
76.23
107.75
137.28
Total Assets
1,239.55
1,222.54
1,217.69
1,188.77
945.75
845.58
729.41
691.87
310.70
284.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Jun 06
Jun 05
Cash From Operating Activity
122.85
132.11
122.72
88.64
113.34
109.04
98.81
68.69
36.99
6.11
PBT
28.57
-9.31
48.40
90.94
100.58
109.55
72.32
48.55
42.96
36.65
Adjustment
99.51
89.35
97.67
64.60
76.29
65.21
50.38
47.14
6.77
4.11
Changes in Working Capital
-1.49
55.62
-13.23
-43.25
-36.12
-41.01
-9.16
-18.57
-5.99
-26.02
Cash after chg. in Working capital
126.60
135.66
132.83
112.29
140.75
133.75
113.53
77.12
43.73
14.74
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-3.75
-3.55
-10.12
-23.65
-27.41
-24.71
-14.72
-8.43
-6.74
-8.63
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-55.93
-103.76
-135.43
-170.55
-111.96
-88.41
-40.98
-42.61
-15.75
-89.60
Net Fixed Assets
-57.37
-99.41
-160.40
-163.74
-86.39
-84.46
-40.81
-349.01
-29.62
Net Investments
-0.01
0.17
0.21
15.47
-17.65
-0.19
-0.05
11.09
33.74
Others
1.45
-4.52
24.76
-22.28
-7.92
-3.76
-0.12
295.31
-19.87
Cash from Financing Activity
-63.95
-16.14
-38.77
131.57
-1.48
-19.92
-58.98
-24.41
-24.61
94.50
Net Cash Inflow / Outflow
2.97
12.22
-51.48
49.66
-0.11
0.70
-1.15
1.67
-3.38
11.01
Opening Cash & Equivalents
20.80
8.58
60.06
10.40
10.47
9.77
10.92
9.25
28.58
17.57
Closing Cash & Equivalent
23.76
20.80
8.58
60.06
10.36
10.47
9.77
10.92
25.20
28.58

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Jun 06
Jun 05
Book Value (Rs.)
73.75
71.69
73.25
70.68
62.56
56.30
49.61
44.94
22.28
19.62
ROA
1.96%
-0.24%
3.42%
7.22%
9.15%
10.52%
8.17%
8.53%
10.57%
8.79%
ROE
3.60%
-0.43%
6.21%
12.55%
14.96%
16.97%
13.32%
13.98%
16.96%
14.40%
ROCE
5.78%
1.23%
7.62%
11.80%
16.72%
20.63%
16.84%
18.33%
21.31%
18.06%
Fixed Asset Turnover
1.07
1.06
1.26
1.55
1.69
1.69
1.61
2.10
2.00
2.08
Receivable days
66.96
76.39
74.23
67.31
62.31
61.67
64.94
59.83
106.60
125.29
Inventory Days
64.61
71.01
66.40
58.84
57.17
54.49
49.80
36.61
44.48
50.93
Payable days
67.82
71.91
66.57
61.79
56.58
52.08
43.51
39.89
77.53
93.34
Cash Conversion Cycle
63.74
75.49
74.06
64.37
62.91
64.09
71.24
56.55
73.55
82.88
Total Debt/Equity
0.39
0.45
0.42
0.43
0.24
0.19
0.20
0.29
0.18
0.29
Interest Cover
2.09
0.56
3.06
15.64
8.98
11.35
4.82
3.22
8.41
10.77

News Update:


  • Indoco Remedies launches Favipiravir 400 mg tablets in India
    28th Sep 2020, 09:00 AM

    Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance

    Read More
  • Indoco Remedies gets USFDA’s nod for Apixaban Tablets
    14th Sep 2020, 10:34 AM

    It is used for patients with health problems caused by a blood clot

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.